Jump Financial, LLC Nektar Therapeutics Transaction History

Jump Financial, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 21, 2024	BUY	$0.64 - $3.15 $12,672 - $62,370	19,800 New	19,800 $13,000
Q1 2023 May 03, 2023	BUY	$0.64 - $3.15 $12,672 - $62,370	19,800 New	19,800 $13,000
Q3 2022 Nov 07, 2022	SELL	$3.04 - $5.14 $103,846 - $175,582	-34,160 Reduced 19.68%	139,400 $446,000
Q2 2022 Aug 09, 2022	BUY	$3.17 - $6.17 $443,530 - $863,275	139,915 Added 415.86%	173,560 $659,000
Q1 2022 May 12, 2022	BUY	$4.16 - $13.72 $139,963 - $461,609	33,645 New	33,645 $181,000
Q2 2021 Aug 13, 2021	SELL	$16.52 - $20.4 $388,220 - $479,399	-23,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $389,159 - $598,310	23,500 New	23,500 $470,000

152

130M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $150M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.